Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates a Neutral rating on Intellia Therapeutics (NTLA) and maintains a $29 price target.

April 23, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten reaffirmed a Neutral rating on Intellia Therapeutics with a $29 price target.
The reaffirmation of a Neutral rating and maintenance of the price target suggests no significant short-term price movement is expected. The analyst's view is likely based on current market conditions and company performance, indicating stability but no immediate growth catalysts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100